Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

China Fine Tunes its VC/PE Rules

publication date: Nov 23, 2007
China is about to put into effect new guidelines for venture capital and private equity. The rules, contained in Circular 57, define areas of investment that are preferred, restricted and prohibited, maintaining the overall goal of steering capital toward building high-tech industries in China. Circular 57 will go into effect on December 1, 2007, replacing guidelines that had been in effect since 2004. As detailed by a report issued by Zero2IPO, the new rules modify the preferred/prohibited areas of investment, without changing the fundamental underlying policy.  We look at how biotech is affected...


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital